Telix Financial Statements From 2010 to 2025

Stocks . Australia . 
Stock . Telix Pharmaceuticals
TLX Stock   28.46  1.92  6.32%   
Telix Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Telix Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Telix Pharmaceuticals financial statements helps investors assess Telix Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Telix Pharmaceuticals' valuation are summarized below:
Gross Profit
483.9 M
Profit Margin
0.0637
Market Capitalization
9.5 B
Enterprise Value Revenue
11.9986
Revenue
783.2 M
There are currently eighty-nine fundamental trend indicators for Telix Pharmaceuticals that can be evaluated and compared over time across competition. All traders should double-check Telix Pharmaceuticals' current fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.

Telix Pharmaceuticals Total Revenue

822.37 Million

Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 38.3 M, Other Operating Expenses of 736.1 M or Operating Income of 86.2 M, as well as many indicators such as . Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Telix Pharmaceuticals Technical models . Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Telix Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding238.2 M350.8 M195.8 M
Slightly volatile
Total Assets1.6 B1.5 B286.8 M
Slightly volatile
Total Current Liabilities347.5 M330.9 M63 M
Slightly volatile
Total Stockholder Equity596.6 M568.2 M122 M
Slightly volatile
Property Plant And Equipment Net57 M54.3 M11.3 M
Slightly volatile
Accounts Payable72.1 M68.7 M13.8 M
Slightly volatile
Cash745.9 M710.3 M138.2 M
Slightly volatile
Non Current Assets Total627.8 M597.9 M107.6 M
Slightly volatile
Cash And Short Term Investments745.9 M710.3 M138.2 M
Slightly volatile
Net Receivables166.9 M159 M30.6 M
Slightly volatile
Common Stock Total Equity201.7 M192.1 M103.4 M
Slightly volatile
Liabilities And Stockholders Equity1.6 B1.5 B286.8 M
Slightly volatile
Non Current Liabilities Total648.2 M617.3 M101.4 M
Slightly volatile
Total Liabilities995.6 M948.2 M164.4 M
Slightly volatile
Property Plant And Equipment Gross66.8 M63.6 M13.2 M
Slightly volatile
Total Current Assets964.5 M918.6 M179.2 M
Slightly volatile
Common Stock538.9 M513.2 M175 M
Slightly volatile
Short and Long Term Debt Total610.5 M581.4 M77 M
Slightly volatile
Other Current Liabilities189.9 M180.9 M35.4 M
Slightly volatile
Other Liabilities96.6 M92 M32 M
Slightly volatile
Other Assets4.8 M4.6 M1.2 M
Slightly volatile
Good Will112 M106.6 M15.5 M
Slightly volatile
Inventory40.1 M38.1 M7 M
Slightly volatile
Other Current Assets5.9 M11.1 M3.2 M
Slightly volatile
Net Invested Capital1.2 B1.1 B198.8 M
Slightly volatile
Short and Long Term Debt19.9 M19 M2.8 M
Slightly volatile
Net Working Capital617 M587.7 M119 M
Slightly volatile
Short Term Debt22.6 M21.5 M3.3 M
Slightly volatile
Intangible Assets325 M309.5 M62.6 M
Slightly volatile
Property Plant Equipment22.7 M21.7 M6 M
Slightly volatile
Current Deferred Revenue7.4 M11.2 M5 M
Slightly volatile
Non Current Liabilities Other27.2 M30.4 M17.8 M
Slightly volatile
Capital Lease Obligations5.8 M10.6 M3.1 M
Slightly volatile
Long Term Investments7.3 M6.1 M11.6 M
Slightly volatile

Telix Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses736.1 M701.1 M146.5 M
Slightly volatile
Depreciation And Amortization10.9 M10.4 M3 M
Slightly volatile
Selling General Administrative123.5 M117.7 M28.6 M
Slightly volatile
Research Development204.4 M194.6 M42.9 M
Slightly volatile
Interest Income11.4 M10.9 M1.8 M
Slightly volatile
Selling And Marketing Expenses121 M115.2 M19.8 M
Slightly volatile
Reconciled Depreciation4.2 M7.8 M2.4 M
Slightly volatile

Telix Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation8.4 M8 M2.7 M
Slightly volatile
Capital Expenditures35.7 M34 M6.1 M
Slightly volatile
Stock Based Compensation10.6 M10.1 M2.8 M
Slightly volatile
Dividends Paid203.4 M193.7 M90.3 M
Slightly volatile
End Period Cash Flow745.9 M710.3 M141 M
Slightly volatile
Issuance Of Capital Stock949 K999 K42.6 M
Pretty Stable

Telix Fundamental Market Drivers

Forward Price Earnings62.5
Cash And Short Term Investments710.3 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Telix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Telix Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Telix Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.2 M7.4 M
Total Revenue783.2 M822.4 M
Cost Of Revenue273.5 M287.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY